MOTS-c

MOTS-c is a 16-amino-acid peptide encoded inside mitochondrial DNA, identified by a USC research team in 2015. Most peptides are encoded in nuclear DNA. MOTS-c is one of a small group encoded in the mitochondrion itself, and it appears to act as a metabolic signal between mitochondria and the rest of the cell.

Mechanistically, MOTS-c activates AMPK, the cellular fuel-sensing pathway. In animal work, it improves insulin sensitivity, increases GLUT4 expression in skeletal muscle, and reduces fat accumulation on a high-fat diet. Circulating MOTS-c is lower in patients with type 2 diabetes than in matched controls, which has driven much of the human interest.

The native MOTS-c peptide does not yet have a published human efficacy trial. A MOTS-c-derived analog (CB4211) reached a published Phase 1 safety study in obese adults with non-alcoholic fatty liver disease. We use this protocol with that evidence picture in mind: strong mechanism and animal data, limited but promising early human data.

MOTS-c is dosed every two or three days rather than daily, which fits its mechanism as a periodic metabolic signal. The 8 to 12 week cycle gives time for the pathway-level effects (AMPK activation, glucose handling, training adaptation) to add up.

Persistent, painless injection-site bumps were reported in the published Phase 1 trial of the related CB4211 analog. Some patients in our clinical experience notice the same. They tend to fade between cycles.

We talk through any insulin sensitivity or glucose handling concerns before starting, especially if you’re on insulin or an insulin-stimulating diabetes medication. AMPK activation introduces a theoretical hypoglycemia consideration in that group.

Metabolic work is rarely about one peptide. This protocol is often used to supplement other services like medical weight management, the GLP-1 program, and testosterone optimization.